No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Pacur To Acquire CAROLEX To Expand Global Position And Customer Reach

Editor: What To Know

  • Pacur, LLC, a market leading supplier of specialty plastic packaging materials for the medical device industry, announced today that it has signed a definitive agreement to acquire CAROLEX SAS, a polyethylene terephthalate glycol (“PETG”) sheet extruder based in France.
  • We are excited to join forces with Sylvain and the entire CAROLEX team and to develop a strong partnership in technology and customer satisfaction.
  • Under epsotech, we strengthened our production capacity and developed a world-class service capability, and we are now eager to join Pacur to support our next phase of growth.

Pacur, LLC, a market leading supplier of specialty plastic packaging materials for the medical device industry, announced today that it has signed a definitive agreement to acquire CAROLEX SAS, a polyethylene terephthalate glycol (“PETG”) sheet extruder based in France. The acquisition strengthens Pacur’s medical device focus in Europe and extrusion capabilities to meet the global demands of customers.

Pacur is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices. The company also produces sheet for certain specialty graphics, pharmaceutical packaging, and food packaging applications.

CAROLEX represents Pacur’s first acquisition and extends the company’s best-in-class customer service and reputation for quality into Europe. Oshkosh, WI-based Pacur is acquiring CAROLEX from epsotech Holding GmbH, a supplier of primarily thick gauge extruded plastic sheet with seven other factories in Europe. Pacur is a portfolio company of middle-market private equity firm Gryphon Investors, which invested in Pacur in 2020. Terms of the transaction, which is expected to close by year end, were not disclosed.

The CAROLEX management team will remain in place, led by Managing Director Sylvain Forestier.

John Carlson, CEO of Pacur said, “The past two years have certainly highlighted how important the entire medical supply chain has become, and has reinforced Pacur’s commitment to increasing our global presence. We are excited to join forces with Sylvain and the entire CAROLEX team and to develop a strong partnership in technology and customer satisfaction. We look forward to investing in Carolex and bringing Pacur’s market-leading capabilities in product innovation to Carolex’s European customers.”

Mr. Forestier commented, “We are delighted to become part of a top-notch global supplier. Under epsotech, we strengthened our production capacity and developed a world-class service capability, and we are now eager to join Pacur to support our next phase of growth. We look forward to continuing our commitment to innovation and leadership and gaining increased resources to better serve our customers.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy